Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of AD-228B vs AD-2284 in Healthy Volunteers
NCT06884098Phase 1Recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Mar 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ezetimibe and pitavastatin in hypercholesterolemia (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Maximum concentration of drug in plasma and Area under the plasma concentration-time curve during dosing interval. Started Mar 2025; status: recruiting.
02
Drugs
ezetimibepitavastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06884098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06884098.